We track VO2 max. We track HRV. We obsess over ApoB. Almost nobody tracks the one skeletal metric that quietly predicts whether a bad fall in your 70s turns into a bruise or a death sentence. 🦴 Bone density doesn’t trend on wellness podcasts because it doesn’t feel urgent, no dramatic before-and-after, no daily biofeedback, just a slow, invisible drawdown that shows up on an imaging report you probably haven’t had done. That silence is the problem. Osteoporosis has no symptoms until the moment it has a very serious one, and by then the numbers get grim fast.
The disease with no symptoms until it’s a hospital bed
Bone isn’t static scaffolding. It’s constantly being broken down by cells called osteoclasts and rebuilt by cells called osteoblasts, a churn that stays roughly balanced through your twenties. 🔬 Peak bone mass is generally reached by your mid-thirties. After that, the demolition crew starts slightly outpacing the construction crew, and the gap widens with age, and sharply during the menopause transition, when we’ve previously reported women can lose 5% to 10% of bone mineral density in a few short years. 📉
Doctors measure this with a dual-energy X-ray absorptiometry scan, or DEXA, which produces a T-score comparing your bone density to that of a healthy young adult. 🦴 A T-score of -1.0 to -2.5 means osteopenia, the precursor stage. Anything at -2.5 or below is osteoporosis. A few numbers worth sitting with:
Roughly one in two women and one in four men over 50 will experience a fragility fracture in their remaining lifetime
Osteoporotic fractures cause an estimated 432,000 U.S. hospital admissions and 180,000 nursing home admissions annually
The disease is sometimes called the “silent epidemic” in clinical literature, precisely because it produces zero symptoms until a bone actually breaks
Hip, spine, and wrist fractures are the three most common sites, and hip fractures carry by far the worst outlook
Here’s a question worth asking yourself honestly: do you actually know your T-score, or are you assuming your bones are fine because nothing hurts yet?
The mortality numbers hiding behind a hip fracture
This is where “silent” stops sounding harmless. A 2026 meta-analysis pooling 28 U.S. studies and more than 835,000 patients found one-year mortality after hip fracture averaged 21.8%, ranging as high as 54.4% depending on the population studied. 💀 A separate large retrospective cohort using the TriNetX health records network, tracking older adults with a first-time long bone fracture, found hip fractures carried a one-year mortality rate of 27.9%, a relative risk of 4.86 compared with age-matched patients who hadn’t fractured anything. That’s not a modest bump. That’s nearly five times the baseline risk of dying within a year. ⚠️
The Osteoporotic Fractures in Men (MrOS) study adds a subtler, arguably more useful data point: you don’t need to break a bone to be at elevated risk. Researchers tracked femoral neck bone density in 4,400 older men over roughly eight years and found that men with accelerated bone loss, defined by DEXA trend rather than a single reading, had a 44% higher risk of all-cause mortality than men whose bone density held steady, even without a fracture ever occurring (hazard ratio 1.44, 95% CI 1.23 to 1.68). A parallel NHANES cohort study of nearly 3,000 postmenopausal women found the same pattern: mortality rose significantly once femoral bone density crossed the osteoporotic threshold. 🔬 A quick summary of what these four studies actually found:
28-study meta-analysis, 835,226 patients: 21.8% average one-year mortality after hip fracture
TriNetX cohort: 27.9% one-year mortality, nearly five times the risk of matched non-fracture controls
MrOS study, 4,400 men, 8-year follow-up: 44% higher mortality with accelerated bone loss, no fracture required
NHANES cohort, nearly 3,000 postmenopausal women: mortality rose once bone density crossed the osteoporotic threshold
We should be honest about what these numbers do and don’t show. All four are observational studies in humans, not randomized trials, so bone loss is traveling alongside frailty, comorbidity, and reduced mobility rather than acting entirely alone as a cause of death. But the dose-response relationship, more bone loss tracking with more risk, and the consistency across independent cohorts of men and women, is exactly the pattern epidemiologists take seriously rather than dismiss.
Screening finally caught up, mostly
For a long time, the honest answer to “when should I get a bone scan” was murky. That changed in January 2025, when the U.S. Preventive Services Task Force issued an updated recommendation: all women 65 and older should be screened (a B-grade recommendation), and postmenopausal women younger than 65 with elevated fracture risk should be screened using a DEXA scan rather than a risk-assessment questionnaire alone, a meaningful upgrade from the 2018 guidance. 📋 Task Force member Dr. Esa Davis put the rationale plainly: too often, the first sign of osteoporosis is a broken bone, and screening exists to get ahead of that.
Men got left out, and that gap deserves more attention than it gets. 🧬 The USPSTF issued an “I statement” for men, meaning the evidence is currently insufficient to weigh benefits against harms, not that men are at low risk. In fact, research summarized by clinical reviewers notes men are more likely to die following an osteoporosis-related fracture than women are, even though they’re diagnosed less often and screened even less. If you’re a man over 65 with risk factors, that guideline gap is a conversation to start yourself rather than wait for a form letter from your doctor’s office. ⚠️
A few practical screening notes:
A T-score of -2.5 or lower confirms osteoporosis; -1.0 to -2.5 is osteopenia
Risk factors that justify earlier screening include low body weight, smoking, a personal or family history of fracture, rheumatoid arthritis, and long-term steroid use
The FRAX tool estimates your 10-year fracture probability and is worth asking your doctor to run alongside or before a scan
One scan is a snapshot. A second scan two years later, showing the trend, is where the real signal lives
What actually moves the needle
Here’s the genuinely good news: bone responds to mechanical stress at any age, and the evidence for exercise is stronger than most people assume. The LIFTMOR trial, published in the Journal of Bone and Mineral Research, put postmenopausal women with low bone mass, including diagnosed osteoporosis, through eight months of twice-weekly high-intensity resistance and impact training at more than 85% of their one-rep max. Lumbar spine bone density rose 2.9% in that group while a low-intensity comparison group lost 1.2%, adherence exceeded 90%, and a follow-up safety analysis found no vertebral fractures from the loading. 💪 A broader 2025 meta-analysis of 17 randomized trials and 690 postmenopausal women confirmed the pattern at the lumbar spine and femoral neck more generally, meaning LIFTMOR wasn’t a fluke.
For higher-risk cases, the drug landscape has genuinely changed too. 💊 Romosozumab (brand name Evenity), approved in 2019, works differently from older bisphosphonates: it’s an anabolic agent that builds new bone rather than only slowing its breakdown. Worth flagging honestly, since this is industry-funded trial data from manufacturer Amgen: the ARCH trial found a small but real imbalance in cardiovascular events, 50 in the romosozumab group versus 38 on alendronate, which led the FDA to require a boxed warning and limit the drug to a 12-month course, followed by an anti-resorptive medication. It’s not a first-line option for everyone, and your cardiovascular history genuinely matters in that conversation. 🩺 For anyone tracking how quickly the osteoporosis treatment landscape is shifting between anabolics, bisphosphonates, and denosumab, LongevityHub Pro has you covered on the trial data and regulatory detail a single article can’t hold.
Nutrition plays a supporting role rather than a starring one. Vitamin D drives calcium absorption in the gut, and pairing it with vitamin K2 helps direct that calcium toward bone rather than arterial walls, a mechanism we’ve covered in more depth in our piece on the supplements doctors over 50 actually take. Supplementing without a documented deficiency shows limited additional benefit, so testing your levels first beats guessing. A rough hierarchy of what the evidence actually supports, strongest first:
Loaded resistance and impact training, the single best-documented lever, per LIFTMOR and the broader meta-analysis above
Correcting a genuine vitamin D or calcium deficiency, confirmed by blood work rather than assumed
Anabolic or anti-resorptive medication for those already diagnosed with osteoporosis or at high fracture risk
General weight-bearing activity like walking, which helps but produces a smaller effect than true resistance loading
What to actually do about it
None of this requires waiting for a crisis. 📋 A short, concrete list:
If you’re a woman 65 or older, ask your doctor for a DEXA scan now if you haven’t had one; it’s covered under current USPSTF guidance
If you’re a postmenopausal woman under 65, or a man over 65, ask your doctor to run a FRAX score even if a scan isn’t automatically offered
Start or maintain resistance training that includes real loading, not just light bands, twice weekly if your bones can tolerate it 💪
Get vitamin D and calcium levels tested rather than supplementing blindly
If you’ve already had a scan, ask for the actual T-score and file it somewhere you’ll find again in two years, since the trend matters more than the single number
We covered the earliest signs of this decline in our perimenopause longevity checklist, and the safest way to train around it in our injury-proof guide to strength training after 50, so the tools already exist. 🦴 The only missing piece, for most people, is simply asking for the number. So here’s the honest question: when was the last time you actually saw your own T-score, and what would it take to find out this month instead of after something breaks?